Scoop: White House drops Heidi Overton's FDA nomination
The White House had tried to shore up her nomination Monday, posting on social media an account from the former dean of the University of New Mexico School of Medicine supporting Overton's confirmation.
- Zoom in: Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by President Trump in August.
- What's next: The HELP committee had been scheduled to vote on Overton's nomination on Wednesday.
- Why it matters: The decision means the Trump administration will have to find a new candidate to lead the FDA as HHS Secretary Robert F.
The White House is dropping Heidi Overton 's nomination to lead the Food and Drug Administration because of a lack of congressional support, Axios has learned.
"FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation," a senior administration official told Axios late Tuesday.
- The backstory: Her nomination faced opposition from Democrats and skepticism from some Republican senators, including Sen.
- The FDA has been led by acting Commissioner Kyle Diamantas since Marty Makary resigned in May.
- She had drawn criticism from segments of the MAHA movement that saw her siding with health and agriculture interests and helping undermine Kennedy agenda.
- Antiabortion forces also questioned her commitment to tightening rules for prescribing the abortion pill mifepristone.
- Bill Cassidy (R-La.), chair of the Senate's Health, Education, Labor and Pensions (HELP) Committee.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →